Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Aspirin and the Risk of Microscopic Hematuria in Asymptomatic Screened Population

This study has been completed.
Seoul National University Bundang Hospital
Information provided by (Responsible Party):
Sang Eun Lee, Seoul National University Bundang Hospital Identifier:
First received: June 6, 2012
Last updated: August 27, 2012
Last verified: August 2012
Aspirin can increase the risk of bleeding tendency. However, correlation between aspirin treatment and hematuria in general population is not well known. The investigators will evaluate whether daily use of aspirin increase the risk of microscopic hematuria in healthy large screened populations.

Asymptomatic General Population
Microscopic Hematuria

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective

Resource links provided by NLM:

Further study details as provided by Sang Eun Lee, Seoul National University Bundang Hospital:

Primary Outcome Measures:
  • Incidence rate of the microscopic hematuria [ Time Frame: at the screening ]
    >4 RBC/HPF in urine microscopy

Secondary Outcome Measures:
  • Detection rate of significant cause for microscopic hematuria [ Time Frame: whitin 12 months after screening ]
    • Among participants who had microscopic hematuria at the screening
    • By imaging study or cystoscopy
    • At the screening or within 12 months after screening
    • Significant cause for microscopic hematuria

      1. urinary stone
      2. renal mass (benign or malignant / not simple cyst)
      3. urothelial cancer
      4. other lesions (clinically relevant lesions determined by researchers)

  • Incidence rate of persistent microscopic hematuria [ Time Frame: within 12 months ]
    • Among participants who had microscopic hematuria at the screening
    • Determined by repeated urine microscopy

Enrollment: 60048
Study Start Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years to 89 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Asymptomatic general population who underwent general health screening program

Inclusion Criteria:

  • Age ≥ 20 years, male or female

Exclusion Criteria:

  • No result of urinalysis
  • No record of medical history (including medication)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01615315

Korea, Republic of
Seoul National University Bundang Hospital
Seongnam, Gyeonggi-do, Korea, Republic of, 463-707
Sponsors and Collaborators
Seoul National University Hospital
Seoul National University Bundang Hospital
Principal Investigator: Sang Eun Lee, Seoul National University Bundang Hospital
  More Information

Responsible Party: Sang Eun Lee, Professor, Seoul National University Bundang Hospital Identifier: NCT01615315     History of Changes
Other Study ID Numbers: SNUBH-URO-2012-01
Study First Received: June 6, 2012
Last Updated: August 27, 2012

Keywords provided by Sang Eun Lee, Seoul National University Bundang Hospital:
microscopic hematuria

Additional relevant MeSH terms:
Urination Disorders
Urologic Diseases
Pathologic Processes
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics processed this record on May 25, 2017